Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $59.1 million.

  • Vanda Pharmaceuticals' Shares Outstanding (Diluted Average) rose 142.38% to $59.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.1 million, marking a year-over-year increase of 142.38%. This contributed to the annual value of $58.1 million for FY2024, which is 102.71% up from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $59.1 million for Q3 2025, which was up 142.38% from $59.0 million recorded in Q2 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $59.1 million during Q3 2025, and registered a low of $56.1 million during Q1 2022.
  • In the last 5 years, Vanda Pharmaceuticals' Shares Outstanding (Diluted Average) had a median value of $57.5 million in 2023 and averaged $57.5 million.
  • In the last 5 years, Vanda Pharmaceuticals' Shares Outstanding (Diluted Average) surged by 331.78% in 2021 and then plummeted by 70.76% in 2022.
  • Vanda Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $56.9 million in 2021, then grew by 0.11% to $57.0 million in 2022, then grew by 1.01% to $57.6 million in 2023, then increased by 1.03% to $58.1 million in 2024, then rose by 1.62% to $59.1 million in 2025.
  • Its last three reported values are $59.1 million in Q3 2025, $59.0 million for Q2 2025, and $58.5 million during Q1 2025.